Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
7.51
+0.01 (0.13%)
At close: Jan 26, 2026, 4:00 PM EST
7.49
-0.02 (-0.27%)
Pre-market: Jan 27, 2026, 4:00 AM EST
Lexeo Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
61
Market Cap
548.13M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 654.00K | -1.00M | -60.53% |
| Dec 31, 2021 | 1.66M | 1.14M | 219.59% |
| Dec 31, 2020 | 518.48K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Keros Therapeutics | 246.72M |
| CorMedix | 214.30M |
| Ginkgo Bioworks Holdings | 180.61M |
| Prothena Corporation | 11.79M |
| Ocugen | 5.37M |
| Lyell Immunopharma | 41.00K |
LXEO News
- 12 days ago - Lexeo Therapeutics, Inc. (LXEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 14 days ago - Lexeo Therapeutics, Inc. (LXEO) Discusses Preliminary Data From Phase I/II Trial of LX2020 for PKP2-Associated Arrhythmogenic Cardiomyopathy Transcript - Seeking Alpha
- 14 days ago - Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy - GlobeNewsWire
- 5 weeks ago - Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Lexeo Therapeutics, Inc. (LXEO) Clinician Perspectives on Holistic Management of PKP2-Associated Arrhythmogenic Cardiomyopathy Transcript - Seeking Alpha
- 7 weeks ago - Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum - GlobeNewsWire
- 2 months ago - Lexeo Therapeutics: Behind The Rebound - Seeking Alpha
- 2 months ago - Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights - GlobeNewsWire